SUVN-502

DRUG2 trials

Sponsors

Suven Life Sciences Limited

Conditions

Alzheimer DiseaseAlzheimer's DiseaseCognition DisordersDementia

Phase 2

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

CompletedNCT02580305

Suven Life Sciences LimitedAlzheimer's Disease

Start: 2015-09-30End: 2019-11-07Updated: 2023-06-09

Unknown Phase

Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease

Suven Life Sciences LimitedAlzheimer Disease, Cognition Disorders, Dementia

Updated: 2020-09-29

Related Papers

Clinical and Non‐clinical Evidence Supporting the Development of Masupirdine (SUVN‐502) for the Management of Agitation in Alzheimer’s Disease

Alzheimer s & Dementia2025-12-01

Masupirdine (SUVN‐502): Phase‐3 Study for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type, an Update

Alzheimer s & Dementia2024-12-01

Masupirdine (SUVN‐502) for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type: Preliminary Efficacy and Phase‐3 Study Design

Alzheimer s & Dementia2023-12-011 citations

Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study.

2022-07-314 citations

Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study

Alzheimer s & Dementia Translational Research & Clinical Interventions2022-01-0127 citations

Effect of Age, Cognitive Impairment Severity, and Duration of Disease on Efficacy of Masupirdine in Moderate Alzheimer's Disease Patients: A Post Hoc Analysis of a Phase-2 Randomized Placebo Controlled Study Results

Medical Research Archives2022-01-01